Article ISI
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  (2023)

KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER

Tewari, Krishnansu Sujata; Keefe, Stephen Michael

Más información

Título según WOS: KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Título de la Revista: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volumen: 33
Editorial: BMJ Publishing Group
Fecha de publicación: 2023
Página de inicio: A420
Página final: A420
DOI:

10.1136/ijgc-2023-ESGO.886
Notas: ISI